Press Releases

Download Vicor Information

Investor Presentation (pdf)
2Q10 Shareholder Letter (pdf)

Related Links

SEC Filings

Current Quote
Standard & Poor’s Stock Report Code Of Conduct & Ethics

Ticker Symbol
VCRT.OB

Shares Outstanding
~45,400,000 (fully diluted)

Independent CPA
Daszkal Bolton, LLP

Securities Counsel
Akerman Senterfitt

Patent Counsel
Arnall Golden Gregory LLP

Investors

  • Home
  • Products
    • PD2i Technology
        A New Vital Sign
    • PD2i Analyzer™
        Heartrate Variability and
        Diabetic Autonomic Neuropathy
    • PD2i CA™
        Cardiac Mortality
    • PD2i VS™
        Civilian and Military
        Trauma Triage
  • Clinicians
    • Clinicians Overview
    • Papers and Presentations
  • Investors
    • Investors Overview
    • Governance
    • Research
  • About Vicor
    • Overview
    • Message from the CEO
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Intellectual Property
    • Alliances
    • Vicor Therapeutics
  • News
    • News from Vicor
      Latest News
    • 2010 News
    • 2009 News
    • Vicor in the News
  • Contact
    • Contact Vicor
  • Investors Overview
  • Governance
  • Research

Research

8/11
Opus Group Financial
4/11
Opus Group Financial
2/11
Opus Group Financial
2/11
Zaks Equity Research
11/10
Opus Group Financial
9/10
Zaks Equity Research
8/10
Opus Group Financial
5/10
Zaks Equity Research
4/10
Zaks Equity Research
1/10
Vista Partners

space

space

space






Copyright © 2009 Vicor Technologies, Inc.  |  Privacy  |  Terms